BCD-256 + divozilimab

BCD-256 + divozilimab is a combination investigational therapy consisting of the monoclonal antibody BCD-256 and the anti-CD20 monoclonal antibody divozilimab, developed for second- or later-line treatment of mild to moderate systemic lupus erythematosus with skin involvement. BCD-256’s exact molecular target is not publicly described, but divozilimab is a humanized monoclonal antibody targeting CD20 to deplete B cells, thereby modulating autoimmune and inflammatory activity. The combination is being evaluated primarily for safety, pharmacokinetics, immunogenicity, and efficacy in clinical trials supervised by Biocad, with intravenous administration as the primary route[1][5][7]. Divozilimab is also studied for multiple sclerosis and is registered for systemic scleroderma[6].

Other names

BCD-256 + divozilimab